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Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) of leukemic phase is a rare clinical manifestation, but is highly
prevalent with central nervous system involvement (CNSI). Little is known about this rare clinical observation.
Methods: We reviewed the clinical characteristics of 40 DLBCL patients with leukemic phase identified by flow
cytometry and analyzed BCL2 and MYC aberrations by fluorescence in situ hybridization.
Results: The median age of these 40 patients was 46 years (range, 15–75) with 19 men patients. All patients had
bone marrow involvement, and fourteen (35.0%) had CNSI. There were respectively 14 patients (35.0%) had the
BCL2 or MYC gain/amplification and nine of them (22.5%) simultaneously had both aberrations. Compared to those
without CNSI, CNSI was found more commonly in male patients (71.4 vs. 34.6%, p = 0.046), in those with IPI scores
of 4–5 (57.1% vs. 11.5%, p = 0.001), and in those with elevated serum LDH (100 vs. 61.5%, p = 0.007) and both MYC
and BCL2 rearrangement (88.9 vs. 19.4%; p = 0.000). BCL2 and MYC rearrangements were the sole independent
factor correlated with CNSI.
Conclusion: It is possible that both BCL2 and MYC gene aberrations may contribute to the high incidence of CNSI
observed in leukemic phase of patients with DLBCL.
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Background
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon lymphoid neoplasm, which account for 30%-40% of
non-Hodgkin lymphoma (NHL) [1] in the Western coun-
tries and more than 50% of NHL in China. DLBCL is a
heterogeneous group of disorders with variable histo-
logical and clinical behavior. Up to 40% of patients may
have extranodal involvement at diagnosis. The common
extranodal sites include the gastrointestinal tract, bone,
bone marrow, testis, salivary gland, adrenal gland, liver,
kidney, and central nervous system (CNS) [1]. The extent
of extranodal involvement can impact the overall progno-
sis of each patient [2]. For example, patients with CNS in-
volvement, which is observed in up to 2%-8% of patients,
have poorer outcomes [2–5]. Tumor cells circulated in the
peripheral blood (PB) occur rarely in patients with
DLBCL. However, approximately 16% of patients at
leukemic phase have CNS involvement, which is associ-
ated with increased mortality [6]. It remains unknown
why patients with leukemic phase have a higher incidence
of CNS involvement. As the double hit with MYC and
BCL2 gene rearrangements contribute to the high aggres-
sive behavior of DLBCL [7], we analyzed the cytogenetic
aberrations of patients with DLBCL at leukemic phase.
We observed that both BCL-2 and MYC genes gain/
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amplification were strong independent indicators of CNS
involvement in DLBCL patients at leukemic phase.
Methods
Patients
A flow cytometry database was searched to identify patients
with NHL and with circulating lymphoma cells between
August 2001 and May 2012 at Institute of Hematology and
Blood Disease Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College (CAMS &
PUMC). The target antigens for flow cytometry included
CD19, CD20, CD22, CD10, CD23, FMC7, kappa, lambda,
CD3, CD5, CD45, CD11c, CD103 and sIgM. All antibodies
were obtained from BD Biosciences.
Finally, forty patients with de novo DLBCL and with
complete medical records were enrolled in this study. Pa-
tients with secondary DLBCL were excluded by the clinical
course and medical history. Basic demographics (age,
gender), performance status, Ann Arbor stage, presence of
extra nodal sites, chromosome karyotype, bone marrow
biology and peripheral blood morphology, cerebrospinal
fluid (CSF) involvement, hematological parameters, lactate
dehydrogenase (LDH) levels, and treatment outcomes were
assessed. Histologic specimens were reviewed by hemato-
pathologists, including two of the authors of this study,
based on WHO classification [1]. All bone marrow tissues
evaluated in this study were performed at the time of initial
staging. All patients enrolled gave informed consent in ac-
cordance with the Declaration of Helsinki. The study was
approved by the Ethics Committee of CAMS & PUMC.
CNS involvement was defined based on the combin-
ation of clinical CNS manifestations, radiological findings,
and/or examination of the cerebrospinal fluid (CSF). Cy-
tology study of CSF and CNS imaging by brain magnetic
resonance imaging (MRI)/computerized tomography (CT)
were performed for patients with a clinical suspicion of
CNS involvement. The patterns of CNS involvement were
as follows: 3 patients identified as parenchymal involve-
ment, 9 patients with leptomeningeal involvement and 2
patients with combined involvement. Five patients were
presented with CNS involvement at diagnosis and others
at progression or disease recurrence.
Fluorescence In Situ Hybridization (FISH)
Interphase FISH analysis was performed on bone marrow
samples at diagnosis. The DNA probes used were LSI
BCL2 and MYC Dual Color, Break Apart Rearrangement
Probe, LSI IGH/BCL2 Dual Color, Dual Fusion Transloca-
tion Probe and LSI IGH/MYC/CEP 8 Tri-Color Dual
Fusion Probes (purchased from Vysis, USA). Sample prep-
arations and hybridizations were conducted following
manufacturer’s recommendations. Methods for FISH ana-
lysis are described elsewhere [8, 9]. At least 200 cells with
well delineated signals were evaluated. The cut-off for
positive values (mean of normal control + 3SD), deter-
mined from samples of ten cytogenetically normal per-
sons, were 4.5% for LSI BCL2 and MYC Dual Color, Break
Apart Rearrangement Probe and 3.2% for LSI IGH/BCL2
Dual Color, Dual Fusion Translocation Probe and LSI
IGH/MYC/CEP 8 Tri-Color Dual Fusion Probes. Gains
were defined as three copies of the gene studied, whereas
at least four copies were considered as amplifications [10].
Survival and statistical analysis
Overall survival (OS) was measured as the interval
between the date of treatment and the date of death or last
follow-up. Progression-free survival (PFS) was measured
as the interval between the date of treatment and the date
of death from any cause or disease progression. Fisher’s
exact test or chi-square test was used to determine statisti-
cally significant differences between the clinical character-
istics of the two groups. Survival curves were constructed
by the Kaplan-Meier method, and prognostic features
were evaluated on univariate analysis (log-rank test). The
effects of potential prognostic variables on survival were
assessed according to the Cox regression method. P values
<0.05 were considered statistically significant. All calcula-




The clinical characteristics of the 40 patients are presented
in Table 1. In this study, there were a large number of
younger patients, with a median age of 46 years (range
15–75). The median white blood cell (WBC) was 12.32 ×
109/L, while the median percentage of circulating lympho-
matous cells was 35.74% (range, 1–90) as determined by
flow cytometry. Twenty-seven patients (67.5%) had
anemia and half of these patients had reduced platelet at
diagnosis. All of the 40 patients had bone marrow involve-
ment, and 14 patients had CNS involvement. Other extra-
node sites involvement included lung, kidney, pancreas,
adrenal gland, liver, testis, and bowel.
As there was a high percentage of CNS involvement in
these patients at leukemic phase, we compared the clinical
characteristics between patients with or without CNS in-
volvement (Table 1). There was a significant male prefer-
ence, higher elevated LDH percentage and high risk IPI
group in patients with CNS involvement. The median age
of the patients with CNS involvement was also younger
than those without (44 vs. 51 years, p = 0.392).
Cytogenetic aberrations
Using the bone marrow cells, we detected BCL2 andMYC
gene arrangements by FISH. There was no t (14;18)
(q32;q21) abnormality detected by BCL2/IGH Dual
Fusion Translocation Probe. However, 14 patients had
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three or more fusion signal of BCL2 (Fig. 1), which
meant that 35% patients had BCL2 gene gain/amplifica-
tion. Additionally, gain/amplification of MYC was pre-
sented in 14 patients (Fig. 1), with one having
concomitant MYC/IGH translocation. Nine patients ex-
hibited both MYC and BCL2 gene gains/amplifications.
As shown in Fig. 1, gain and amplification always con-
curred in one patient. Some patients display predomin-
ant amplifications with minor gains and others
reversely. So we did not discriminate gain and amplifi-
cation in an individual here and put gain and amplifica-
tion together to analyze and used “abnormality” instead
of “gain” or “amplification” in this manuscript.
Eight of the fourteen patients (57.1%) with BCL2 ab-
normality had CNS involvement, while 6 of 26 patients
(23.1%) that lacked the BCL2 abnormality had CNS in-
volvement (p = 0.043). Eleven of the 14 patients (78.6%)
with MYC abnormality had CNS involvement, which
was significant higher than three of the 26 patients
(11.5%) without MYC abnormality (p < 0.001). Among
the 9 patients with both MYC and BCL2 abnormality,
eight patients had CNS involvement, while only 6 of the
other 31 patients with BCL2 or MYC or no abnormality
had CNS involvement (88.9 vs. 19.4%; p < 0.001).
Other clinical characteristics that were associated with
CNS involvement (as shown above) included gender,
elevated LDH, and high risk IPI group. We performed a
multivariate analysis to determine the relationship
between the clinical characteristics and CNS involvement,
by integrating gender, elevated LDH, high risk IPI, and
concomitant BCL2 and MYC abnormalities. We demon-
strated that concomitant BCL2 and MYC abnormalities
were the only independent factor that correlated with
CNS involvement (relative risk 15.3, 95% confidence
Table 1 the comparison of clinical characteristics between patients with or without CNS involvement
Characteristics With CNS involvement Without CNS involvement P value
N=14 N=26
Age, median (range, year) 44.0 (23.0-62.0) 51.0(15-75) .392
Gender, men, n(%) 9 (34.6%) 10(71.4%) .046
B symptoms, n (%) 10 (71.4%) 15(57.7%) .502
Elevated LDH, n (%) 14 (100%) 16(61.5%) .007
Median WBC×109/l (range) 17.2 (1.2-66.57) 9.58(1.38-40.06) .729
Median Hb, g/l (range) 95.0 (61.0-145.0) 100.5(45.0-141.0) .777
Median PLT, ×109/l (range) 73.5 (20.0-355.0) 113.0(3.0-509.0) .843
International Prognostic .002
Index, n (%) 0 9 (34.6%)
2 6 (42.9%) 14(53.8%)
3 8 (57.1%) 3(11.5%)
4-5 .896
Treatment, n (%) 4 (28.6%) 10(38.5%)
CHOP/CHOP-like 1 (7.1%) 3(11.5%)
R- CHOP/CHOP-like 4 (28.6%) 5(19.2%)
Intensive regimes 5 (35.7%) 8(30.8%)
Fig. 1 Genetic aberrations of BCL2 and MYC gene as detected by FISH. The red arrow indicated gene gain or amplification (three or more
fusion signals)
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interval, 1.4-171.1, p = 0.027). Therefore, there was a
strong association between DLBCL patients with con-
comitant of BCL2 and MYC abnormalities and CNS
involvement.
Treatment and survival
All of the 40 patients included in this study had received
at least 2 cycles of chemotherapy, with median 4 cycles
(range 2–10). As shown in Table 1, fourteen patients had
received CHOP or CHOP-like regimens, while nine
patients had received HyperCVAD/MA alternating
chemotherapy or CHOPE/ EPOCH regimens chemother-
apy. Seventeen patients had received rituximab combin-
ation chemotherapy, including 4 patients with R-CHOP/
CHOP-like regimens and other with R-intensive regimens.
Three patients received R-HyperCVAD/MA regimens as
inductive chemotherapy and then took autologous stem
cell transplantation (ASCT) as consolidation treatment.
Intrathecal chemotherapy was done in patients with CNS
involvement. Eleven patients (27.5%) had reached partial
remission (PR), and fifteen patients (37.5%) with complete
remission or uncertain complete remission (CR/CRu).
Therefore, the overall response rate (ORR) was 62.5%.
The ORR and CR/CRu for the 17 patients treated with
rituximab was 76.4% and 52.9% respectively.
With a median follow-up of 18 months (range 2–93
months), 32 patients had died and the median follow-up
for the surviving patients was 34.5 months (range 22–69
months). The median PFS and OS was 11.0 (95% CI,
6.0-16.0) and 18.0 (95% CI, 8.7-27.3) months, respect-
ively. The median PFS and OS of the patients with CNS
involvement were 5.0 (95%CI, 4.1-5.9) and 8.0 (0.7-15.3)
months, respectively, which were significantly shorter
than those without CNS involvement (median PFS, 25.0
[range, 11.1-38.9 months], p < 0.001; OS, 29.0 [range,
24.5-33.5 months], p = 0.01). DLBCL patients with
concomitant BCL2 and MYC abnormalities also had a
shorter median PFS (5.0 vs.22.5, p = .002) and OS (9.0
vs.27.5, p = .001) than those without the genetic abnor-
mality. Two of the patients receiving ASCT had disease
progression after three months of ASCT, with one
patient surviving over five years.
Discussion
Peripheral blood involvement in patients with DLBCL is
rare. Currently, there are only three large studies have
reported the frequency of PB involvement in DLBCL pa-
tients. In a Japanese study, 1.2% of patients with DLBCL
demonstrated PB involvement [2], while two other stud-
ies from Western countries showed that 4%-5.3% of pa-
tients with DLBCL exhibited PB involvement [11, 12].
However, morphologic examination of peripheral blood
smears revealed that approximately one third of DLB CL
patients with BM involvement also had malignant cell in
PB. These studies did not assess the association between
clinical and cytogenetic characteristics and PB involve-
ment in DLBCL patients. To our knowledge, this study
is the largest to report the clinical characteristics and
outcome of DLBCL patients at leukemic phase [6, 13].
Similar clinical characteristics of leukemic DLBCL were
identified in the study by Murungampurath-John [6], in-
cluding the median age, gender, B symptom, bone marrow
involvement, median WBC and HB, and the distribution
of IPI index. However, in our study, the number of
extranodal site involvement was lower than that of a study
by Murangampurath-John (50 vs. 100%) [6]. CNS
involvement was reported to be 22% in the study by
Muringampurath-John [13], which is lower than that re-
ported in our study (35%). However, the reported number
of CNS involvement in our study and the study by Murin-
gampurath-John was higher than that reported in
other DLBCL patient populations. When comparing
the clinical characteristics between patients with or
without CNS involvement, age was associated with
CNS involvement. Additionally, when compared to
the study by Muringampurath-John, the median WBC
and PLT, and the percentage of circulating lympho-
matous cells in this study were comparable, except
for a higher percentage of patients with high IPI
scores (≥4) in that study (41 vs. 27.5%) [6].
Cytogenetic aberrations are biologic and diagnostic
hallmarks of mature B-cell lymphomas. The t (14;18)
(q32;q21) translocation is the most common transloca-
tion observed in follicular lymphomas [1], which could
potentially transform to DLBCL, [14]. In this study, 35%
DLBCL patients had BCL2 gene gain/amplification and
none were reported having the t (14;18) translocation,
which was consistent with no patients having FL history.
Recently, it was demonstrated that a double-hit lymph-
oma caused by multiple genetic aberrations, such as the
MYC/8q24 locus and BCL2/18q21.3 locus can give rise
to a unique subset of lymphomas. Translocation or amp-
lification of the BCL2 gene occurred in 20-30% of cases
of reported lymphomas [15]. MYC rearrangement have
been reported in up to 10% of an unselected series of
cases and is associated with a complex pattern of genetic
alterations [1]. Most of the MYC translocations occur
with IG genes [16]. However, these cytogenetic aberra-
tions have not been specially detected in DLBCL pa-
tients at leukemic phase. Moreover, gene rearrangement
was the main aberration of BCL2/MYC in DLBCL other
than gene gain/amplification. Some studies have also re-
ported that patients with 18q21.3/BCL2 and 8q24/MYC
genetic rearrangement are at higher risk of having CNS
involvement [16–18]. The incidence of CNS involvement
ranged from 9% to 50% in double-hit (DH) lymphoma
[7, 19, 20]. In this study, the incidence of CNS involve-
ment increased to 88.9% in DLBCL patients at leukemic
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phase with concomitant BCL2 and MYC gain/amplifica-
tion. However, for patients with primary lymphoma of
the CNS (PCNSL), it was reported that up to 8% had
MYC rearrangement and none with BCL2 rearrange-
ments [21]. Therefore, the underlying mechanism of
CNS involvement of leukemic DLBCL may differ from
PCNSL.
PB or CNS involvement or concomitant genetic abnor-
malities of MYC and BCL2 have been reported to be asso-
ciated with poor survival in DLBCL [2, 16, 18]. Patients
with leukemic phase have lower CR rate (44%) even after
rituximab combination chemotherapy, indicating drug-
resistance for this population [13]. In this study, the CR/
CRu rate for the patients treated with rituximab was
52.9%, comparable to previous report (54%) [6]. In this
study, the median OS for all patients was 18 months, with
CNS involvement and both BCL2/MYC dual abnormal-
ities being predictors of poor clinical in DLBCL patients
of leukemic phase. Three patients had received ASCT in
this study. Two patients with CNS involvement reached
CR/CRu after R-HyperCVAD/MA introductive chemo-
therapy but had disease progression even after ASCT. The
other patient remains alive after ASTC, and did not have
CNS involvement. This phenomenon indicates that new
chemotherapy or targeted therapy is needed for these
patients.
Conclusions
Our study demonstrated that patients with DLBCL of
leukemic phase had higher incidence of CNS involvement
and concomitant BCL2 and MYC gene gains/amplifica-
tions. The concomitant of BCL2 and MYC gene gains/am-
plifications was the only independent factor that
correlated with CNS involvement. Additionally, these pa-
tients exhibited a poorer treatment response and survival
despite combination therapy with rituximab and ASCT.
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